USE OF VESSELS ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITORS FOR CANCER TREATMENT

摘要

1. A non-invasive method for examining patients to assess tumor mass, which consists in determining the level of LDH5 in the serum or plasma of a patient, while high LDH5 is a criterion for selecting patients for effective treatment with a VEGF-R inhibitor. ! 2. A non-invasive method for examining patients to assess tumor mass, which consists in determining the level of LDH5 in the patient’s serum or plasma, while a high level of LDH5 in serum / plasma is a criterion for selecting patients for effective treatment with 4-pyridylmethylphthalazine derivative. ! 3. A non-invasive method for examining patients to assess tumor mass, which consists in determining the level of LDH5 in the patient’s serum or plasma, which can be used as a common sign / biomarker of tumor mass, which allows you to evaluate the response to a positive or negative response to treatment with using a VEGF-R inhibitor. ! 4. A non-invasive method for examining patients to assess tumor mass, which consists in determining the level of LDH5 in the patient’s serum or plasma, which can be used as a common sign / biomarker of tumor mass, which allows you to evaluate the response to a positive or negative response to treatment with using a 4-pyridylmethylphthalazine derivative. ! 5. A method for treating patients suffering from cancer of the gastrointestinal tract, genitourinary, lymphatic system and small cell and non-small cell lung cancer, or patients suffering from cancer of the neural scallop cells, and said method is that a patient who is observing